摘要
目的探讨免疫佐剂BCG-CpG-DNA对A群脑膜炎球菌多糖疫苗的作用。方法将不同剂量(5、10、100μg)的免疫佐剂BCG-CpG-DNA与A群脑膜炎球菌多糖疫苗直接混合后,皮下免疫小鼠,与未添加佐剂疫苗比较,ELISA法检测抗原特异性IgG抗体水平,并分析抗体亚类IgG1和IgG2a的水平。结果BCG-CpG-DNA能提高A群脑膜炎球菌多糖疫苗特异性抗体IgG水平,并能促进抗原特异性抗体亚类的产生,其中佐剂中、高剂量(10、100μg)实验组IgG、IgG2a水平与未加入免疫佐剂疫苗之间差异有统计学意义。结论BCG-CpG-DNA对A群脑膜炎球菌多糖疫苗有免疫佐剂作用。
Objective To study adjuvantity of BCG-CpG-DNA from Mycobacterium bovis strain BCG to group A meningococcal polysaccharide antigen. Methods Mice were vaccinated s.c.with group A meningococcal polysaccharide vaccine alone and combined with different doses of BCG-CpG-DNA（5,10,100μg）,then the humoral response were assessed.antigen-specifec IgG and antigen-specifec IgG isotypes were tested by ELISA and analysis of antibody subclasses IgG1 and IgG2a levels. Results BCG-CpG-DNA improved antibody level of antigen-specifec IgG and IgG2a,the middle and high dose（10,100μg）ofBCG-CpG-DNA group are statistically significant（P〈0.05）vs vaccine controll group respectfly.It means that BCG-CpG-DNA induced Th1 type immune responses. Conclusion BCG-CpG-DNA is a potential new immune adjuvant for group A meningococcal polysaccharide vaccine.
出处
《中国医药生物技术》
CSCD
2010年第2期94-97,共4页
Chinese Medicinal Biotechnology
基金
国家高技术研究发展计划(2006AA02A240)
